ANN ARBOR, MI – MAY 10, 2021 – A white paper recently published by Ripple Science revealed that its flagship product, Ripple, empowered its customers to achieve >96% retention across all trials and 99% retention in 78.2% of completed trials, far outpacing industry averages. 

Ripple Science is the leading provider of clinical trial software used by sites, CROs, and study sponsors to assist and automate the patient engagement workflow end-to-end, from first contact to study completion. Ripple has supported over 700 clinical trials involving over 240,000 patients globally, including a large number of Alzheimer’s, dementia, and CNS trials where patient engagement is particularly challenging.

Despite the many challenges impacting clinical trial success, Ripple Science’s product Ripple, showcases a positive impact on one of the most important drivers of clinical trial success,  patient retention. 85% of clinical trials fail, and attrition can have a serious impact on time-to-market for critical medical advances.  Each day of delay is estimated to cost sponsors $600,000 to $8 million per study.

With the onset of COVID-19, Ripple Science has been at the forefront supporting sites conducting COVID trials globally, while helping the industry move rapidly to decentralized (DCT), virtual and hybrid clinical trials. Since attrition is a particular challenge for decentralized clinical trials,  Ripple’s direct-to-patient engagement tools provide the extra effort needed to keep DCT and hybrid trials on track. 

With the evolving democratization of clinical trials, and access moving beyond academic medica